Therefore, these findings enable us to reasonably conclude that AC005592.2 is an oncogene in CRC and may serve as a target for new therapies in CRC, which will provide a new opportunity for CRC patients. This evidence concerns the gene SPRY4-AS1 and colorectal carcinoma.